Notizia - Recent Pharma, Healthcare and Biotech Happenings

EU approves the use of Libtayo for cutaneous squamous cell carcinoma The National Institute for Health and Care Excellence (NICE), in a move to make cancer drugs available to common man, has issued guidelines regarding the funding of Libtayo (cemiplima). Libtayo, co-developed by Sanofi and Regeneron, was granted its first conditional marketing authorization in Europe for advanced cutaneous squamous cell carcinoma (cSCC) patients, who are unable to receive surgery or radiation therapy. It is a fully human monoclonal antibody, which targets the immune checkpoint receptor PD-1 (programmed cell death protein-1) and is the only treatment approved in advanced CSCC therap...